References
Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330. https://doi.org/10.1182/blood-2014-10-567479
Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18(6):806–815. https://doi.org/10.1038/modpathol.3800355
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES (2010) Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol 23(7):991–999. https://doi.org/10.1038/modpathol.2010.72
Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG (2017) Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. J Clin Pathol. https://doi.org/10.1136/jclinpath-2016-204294
Dittus C, Grover N, Ellsworth S, Tan X, Park SI (2018) Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma 59(9):2121–2127. https://doi.org/10.1080/10428194.2017.1416365
Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M (2018) Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. https://doi.org/10.1111/bjh.15156
Castillo JJ, Reagan JL, Sikov WM, Winer ES (2015) Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol 169(3):352–355. https://doi.org/10.1111/bjh.13300
Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien M-L, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J (2019) Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol 37(19):1657–1665. https://doi.org/10.1200/jco.18.00776
Funding
This study was funded by MEXT KAKENHI Grant Number 17K07142.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors KY and SY have received a speaker honorarium from Jansen. Author IM declares that he has no conflict of interest. Author TI declares that he has no conflict of interest. Author SM declares that he has no conflict of interest. Author MO declares that he has no conflict of interest. Author YS declares that he has no conflict of interest. Author SH declares that he has no conflict of interest. Author YF declares that he has no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yoshihara, K., Yoshihara, S., Matsuda, I. et al. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. Ann Hematol 99, 1405–1407 (2020). https://doi.org/10.1007/s00277-020-03975-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03975-x